SELECTBIO - Circulating Biomarkers and Extracellular Vesicles Europe 2024 Keynote Speakers

Home

Agenda

Keynote Speakers

Registration

Exhibition

Venue

Training Courses

Co-Located Conferences

Mario Gimona

Head of Manufacturing, GMP Unit, Paracelsus Medical University Salzburg

Mario Gimona received his PhD in Genetics and Cell Biology in 1990 and spent his postdoctoral period at the Cold Spring Harbor Laboratory in New York. He has led research labs in Austria and Italy and was awarded a Marie Curie Excellent Grant by the European Union in 2004. Since 2012 he heads the GMP stem cell and EV production unit at PMU and leads a team of researchers investigating the potential of MSC-derived EVs and CDVs in regenerative medicine for application in acute spinal cord injury and for the reduction of scar formation following implant-induced injury.

Marcin Jurga

Chief Scientific Officer, EXO Biologics SA

Marcin Jurga, PhD, CSO at EXO Biologics, has been working in the fields of cell-based regenerative medicine and tissue engineering for over 20 years. Marcin Jurga has been leading teams developing EVs drug candidates since 2011.

Sai Kiang Lim

Research Director, Institute of Medical Biology, A*STAR

Dr Sai-Kiang Lim graduated with B.Sc (Hons), NUS. PhD SUNY at Buffalo and did post-doctoral training Columbia University. She led independent research groups at NUMI, NUS (1996-2001), Genome Institute of Singapore (2002-2007) and then Institute of Medical Biology (2007-present). The current research interest in her lab is the study of extracellular vesicles (EVs) for the development of therapeutics and diagnostics as well as artificial lipid membrane vesicles.

Raymond Schiffelers

Professor of Nanomedicine, University Medical Center Utrecht

Raymond Schiffelers studied Bio-Pharmaceutical Sciences at Leiden University (1990-1995). After an industrial traineeship at SmithKline Beecham Pharmaceuticals (UK) he did his PhD in medical microbiology at Erasmus University Rotterdam on liposomal targeting of antimicrobial agents (1996-2001). Subsequently he became post-doc at Utrecht University working on liposomes targeting tumor vasculature. In 2002-2003, at Intradigm Co (USA) he expanded his tumor vasculature-targeting work with polymers for delivery of siRNA. After his return to Utrecht University he became assistant and then associate professor. He received an ERC Consolidator Grant in 2010 to investigate extracellular vesicles as biological drug delivery systems. After he moved to University Medical Center Utrecht in 2011 he became professor of nanomedicine working on bio-inspired and synthetic drug delivery systems. He coordinates two H2020 projects on this topic, B-SMART and EXPERT, is editor for the International Journal of Pharmaceutics, Journal of Controlled Release and Journal of Extracellular Vesicles, and is founder of EXCYTEX-an extracellular vesicle-based company. Since 2021 he also works part-time for Nanocell Therapeutics as VP Preclinical R&D and is president of the ETPN.

Danilo Tagle

Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS)

Dan Tagle is Director of the Office of Special Initiatives at NCATS where he many coordinates efforts towards development of disruptive technologies in translational research. He obtained his Ph.D. in Molecular Biology and Genetics from Wayne State University School of Medicine. He was an NIH National Research Service Award postdoctoral fellow in Human Genetics at the University of Michigan. He has served on numerous committees, advisory boards, and editorial boards. He has authored many scientific publications and has garnered numerous awards, including more recently the Roscoe O. Brady Award for Innovation and Accomplishment, and the Henry J. Heimlich Award for Innovative Medicine.

Valérie Taly

CNRS Research Director, Professor and Group leader Translational Research and Microfluidics, Université Paris Cité

V. Taly is a CNRS research director and group leader of the Translational Research And Microfluidics team within the clinical oncology research unit MEPPOT (personalized medicine pharmacogenomics and therapeutic optimization) in the Cordeliers Research Center (university Paris Cité). Her team performs interdisciplinary researches aiming at developing and validating microfluidic tools for cancer research in close collaboration with clinicians and researchers in oncology and toxicology. Since 2008, she developed droplet-based digital procedures for Cancer diagnosis. Recently, her research has been dedicated to the clinical validation of droplet-based microfluidics for the non-invasive detection of Cancer biomarkers, the highlighting of new Cancer Biomarkers and the development of original tools and procedures for their detection with applications in personalized medicine, cancer recurrence detection and cancer diagnostics. She is co-founder of EMULSEO (2018) and METHYS DX (2021) start up companies.